Brokerages expect that Mylan NV (NASDAQ:MYL) will post earnings of $0.97 per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Mylan’s earnings. The highest EPS estimate is $1.08 and the lowest is $0.88. Mylan posted earnings per share of $1.07 during the same quarter last year, which would suggest a negative year over year growth rate of 9.3%. The business is expected to announce its next earnings results on Wednesday, August 14th.
According to Zacks, analysts expect that Mylan will report full year earnings of $4.28 per share for the current fiscal year, with EPS estimates ranging from $4.03 to $4.46. For the next year, analysts forecast that the company will post earnings of $4.56 per share, with EPS estimates ranging from $4.29 to $4.92. Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that that provide coverage for Mylan.
Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $0.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.03. The firm had revenue of $2.50 billion during the quarter, compared to analysts’ expectations of $2.70 billion. Mylan had a net margin of 2.14% and a return on equity of 18.96%. The firm’s revenue for the quarter was down 7.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.96 earnings per share.
Several research analysts recently issued reports on the stock. BidaskClub cut shares of Mylan from a “hold” rating to a “sell” rating in a report on Monday. Mizuho reissued a “hold” rating on shares of Mylan in a report on Tuesday, May 14th. Morgan Stanley set a $32.00 price target on shares of Mylan and gave the stock a “buy” rating in a report on Wednesday, May 8th. Raymond James set a $31.00 price target on shares of Mylan and gave the stock a “buy” rating in a report on Wednesday, May 8th. Finally, BMO Capital Markets set a $36.00 price target on shares of Mylan and gave the stock a “buy” rating in a report on Wednesday, May 8th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $37.35.
NASDAQ MYL traded down $0.48 during trading hours on Thursday, hitting $19.17. 6,231,318 shares of the stock were exchanged, compared to its average volume of 6,253,940. The stock has a market capitalization of $10.14 billion, a P/E ratio of 4.19, a P/E/G ratio of 1.02 and a beta of 1.44. Mylan has a 12-month low of $18.93 and a 12-month high of $42.50. The company has a quick ratio of 0.85, a current ratio of 1.51 and a debt-to-equity ratio of 1.20.
In other Mylan news, insider Paul Campbell sold 11,533 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $27.50, for a total value of $317,157.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.81% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Global Retirement Partners LLC grew its position in shares of Mylan by 107.1% in the first quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock valued at $27,000 after purchasing an additional 500 shares during the last quarter. Pinnacle Bank grew its position in shares of Mylan by 66.4% in the first quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock valued at $30,000 after purchasing an additional 423 shares during the last quarter. Cresset Asset Management LLC acquired a new stake in shares of Mylan in the first quarter valued at approximately $41,000. Mascoma Wealth Management LLC acquired a new stake in shares of Mylan in the first quarter valued at approximately $47,000. Finally, Kinneret Advisory LLC acquired a new stake in shares of Mylan in the fourth quarter valued at approximately $71,000. Institutional investors and hedge funds own 82.73% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Article: Quiet Period
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.